立即開始
ReutersReuters

Update On Phase 3 Librexia ACS Trial

Refinitiv閱讀少於1分鐘
BMY

Bristol-Myers Squibb Co BMY:

  • UPDATE ON PHASE 3 LIBREXIA ACS TRIAL

  • BRISTOL-MYERS SQUIBB CO - LIBREXIA ACS TRIAL DISCONTINUED DUE TO EFFICACY CONCERNS

  • BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY CONCERNS IDENTIFIED FOR MILVEXIAN

  • BRISTOL-MYERS SQUIBB CO - LIBREXIA AF AND STROKE STUDIES CONTINUE, DATA EXPECTED 2026

Reuters
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
登入或建立一個永久免費帳戶來閱讀此新聞

來自 Reuters 的更多新聞